High dose @entity3593 in XXXX : economic considerations.

@entity1 @entity712 @entity1289 @entity63 @entity3593 @entity204 @entity7634
BACKGROUND AND OBJECTIVES. In Switzerland, @entity712 ( @entity712 ) is one of the ten most common causes of hospitalization in @entity1 older than 65 and the second most common in those over 80 years. 17% of the population in Switzerland is in this age class. The expenditures associated with @entity712 are thus considerable. High doses of the @entity1289 ( @entity1289 ) inhibitor @entity3593 in @entity1 with @entity712 have been shown to significantly reduce the risk of @entity204 or hospitalization for @entity712 and for any reason. The objective of the present study was to analyze the economic implications of using high doses of @entity3593 in the Swiss health care system setting, both from the societal perspective and from that of the Swiss health insurers. @entity1 AND METHODS: Using published data from the ATLAS Trial, we computed the monthly probability of @entity204 and of hospital admission for @entity712 , @entity63 events, other cardiovascular causes and any reason per @entity1 for both arms of the trial. Swiss resource use patterns and Swiss unit costs were used to calculate expected monthly expenditures per @entity1 from the third party payer perspective and from the societal viewpoint. Extensive sensitivity analyses were performed to test the robustness of our results. RESULTS: Expected monthly expenditures from the third party payer perspective are 347 @entity7634 per @entity1 in the low dose group and 319 @entity7634 in the high dose group. This represents expected savings of 28 @entity7634 per @entity1 monthly. Because the public sector pays more than 50% of hospital costs, the savings from the societal viewpoint are greater. Expected monthly costs from the societal perspective are 762 @entity7634 in the low dose group and 670 @entity7634 in the high dose group per @entity1 . This results in expected monthly savings of 92 @entity7634 . Sensitivity analysis shows that the use of high doses of @entity1289 inhibitor @entity3593 does not result in higher health care expenditures for the whole system or even savings through a wide variety of practice patterns and unit costs. CONCLUSIONS: Based on the results of the ATLAS study, high doses of @entity3593 are associated with a reduction in the number of hospitalizations for @entity712 and for any reason and with a statistically non-significant reduction in mortality. The additional expenditures incurred because of prescription of high doses are offset by the savings in hospital costs. These are important considerations, given the increasing number of @entity1 aged 65 and older in Switzerland, and the prevalence of @entity712 in this age group.
